Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Comparing Outcomes of Patients with Secondary AML: Treatment-Related MDS/AML, AML Secondary to Myeloproliferative Neoplasms (t-MPN), and AML with Prior Malignancies

Cecilia Y Arana Yi, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, William G. Wierda, MD, Ph.D., Gautam Borthakur, MD, Alfonso Quintas-Cardama, MD, Marina Konopleva, MD, PhD, Stefan Faderl, MD, Sherry A. Pierce, RN, BS, Michael Andreeff, MD, PhD, Farhad Ravandi, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 3557.

https://doi.org/10.1182/blood.V120.21.3557.3557

Published: 2012

Journal Articles

Efficacy of PRT060318, a Novel Highly Specific SYK Inhibitor, in Acute Lymphoblastic Leukemia (ALL)

Stefan KÖhrer, MD, Greg Coffey, PhD, Ekaterina Kim, MS, Nathalie Y Rosin, PhD, Uma Sinha, PhD, Anjali Pandey, PhD, Medhat Shehata, Ulrich Jäger, Susan M. O'Brien, MD, William G. Wierda, MD, Ph.D., Zeev Estrov, MD, PhD, Deborah Thomas, MD, Hagop M Kantarjian, Jan A. Burger, MD, PhD

Blood (2012) 120 (21): 3532.

https://doi.org/10.1182/blood.V120.21.3532.3532

Published: 2012

Journal Articles

In Vitro Effects of PI3Kδ Inhibitor GS-1101 (Cal-101) in Acute Lymphoblastic Leukemia (ALL)

Nathalie Y Rosin, PhD, Stefan Koehrer, MD, Ekaterina Kim, MS, Susan O'Brien, M.D., William G. Wierda, MD, Ph.D., Deborah A. Thomas, MD, Zeev Estrov, MD, PhD, Hagop M. Kantarjian, MD, Brian J. Lannutti, PhD, Jan A. Burger, MD, PhD

Blood (2012) 120 (21): 3534.

https://doi.org/10.1182/blood.V120.21.3534.3534

Published: 2012

Journal Articles

Signal Transducer and Activator of Transcription (STAT)-3-Dependent Regulation of Non-Coding RNA Genes in Chronic Lymphocytic Leukemia (CLL).

Uri Rozovski, MD, George Calin, MD PhD, Setoyama Tetsirp, Lucilla D'Abundo, David Harris, Ping Li, Zhiming Liu, Srdana Grgurevic, MS, Alessandra Ferrajoli, Stefan Faderl, MD, Jan A. Burger, MD, PhD, Susan M. O'Brien, MD, William G. Wierda, MD, Ph.D., Michael J. Keating, MD, Zeev Estrov, MD

Blood (2012) 120 (21): 2886.

https://doi.org/10.1182/blood.V120.21.2886.2886

Published: 2012

Journal Articles

The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naïve (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients Including Patients with High-Risk (HR) Disease: New and Updated Results of 116 Patients in a Phase Ib/II Study

John C. Byrd, MD, Richard R. Furman, MD, Steven Coutre, MD, Ian W. Flinn, MD, PhD, Jan A. Burger, MD, PhD, Kristie A. Blum, MD, Jeff Sharman, MD, Barbara Grant, MD, Jeffrey A. Jones, MD, MPH, William G. Wierda, MD, Ph.D., Weiqiang Zhao, MD PhD, Nyla A. Heerema, PhD, Amy J. Johnson, PhD, Anh Tran, Fong Clow, ScD, Lori Kunkel, MD, Danelle F. James, M.D, Susan O'Brien, MD

Blood (2012) 120 (21): 189.

https://doi.org/10.1182/blood.V120.21.189.189

Published: 2012

Journal Articles

Is Chronic Lymphocytic Leukemia Still Incurable?

Michael J. Keating, MD, Constantine S Tam, William G. Wierda, MD, Ph.D., Susan O'Brien, M.D., Deborah A. Thomas, MD, Jorge E. Cortes, MD, Susan Lerner, MS, William Plunkett, PhD

Blood (2012) 120 (21): 3929.

https://doi.org/10.1182/blood.V120.21.3929.3929

Published: 2012

Journal Articles

Very High Rate of Leukemic Transformation and Poor Survival in Patients with Lower Risk Myelodysplastic Syndrome (MDS) Who Dynamically Acquire FLT3 Molecular Alteration (FLT3m): Study of 290 MDS Patients with Sequential Mutation Analysis

Koichi Takahashi, MD, Elias J. Jabbour, MD, Xuemei Wang, MS, Hady Ghanem, MD, Naveen Pemmaraju, M.D., Farhad Ravandi, MD, Jorge E. Cortes, MD, Stefan Faderl, MD, Tapan M. Kadia, M.D., Gautam Borthakur, M.D., William G. Wierda, MD, Ph.D., Sherry A. Pierce, RN, BS, Zeev Estrov, MD, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 3802.

https://doi.org/10.1182/blood.V120.21.3802.3802

Published: 2012

Journal Articles

Statins Use Improves the Clinical Outcomes of Salvage Therapy in Relapsed/Refractory CLL

Long Xuan Trinh, MD, Young Kwang Chae, MD, MPH, Preetesh Jain, MD, DM, PhD, Ohad Benjamini, MD, Xuemei Wang, MS, Susan Lerner, MS, William G. Wierda, MD, Ph.D., Zeev Estrov, MD, PhD, Michael J. Keating, MD

Blood (2012) 120 (21): 3931.

https://doi.org/10.1182/blood.V120.21.3931.3931

Published: 2012

Journal Articles

Results of Second Generation Tyrosine Kinase Inhibitor Frontline Therapy in Chronic Myeloid Leukemia with Variant Philadelphia Chromosome

Carlos G. Romo, M.D., Hagop M Kantarjian, M.D., Susan O'Brien, M.D., Alfonso Quintas-Cardama, MD, Steven M. Kornblau, MD, PhD, Stefan Faderl, MD, Alessandra Ferrajoli, M.D., William G. Wierda, MD, Ph.D., Sherry A. Pierce, RN, BS, Elias J. Jabbour, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 3774.

https://doi.org/10.1182/blood.V120.21.3774.3774

Published: 2012

Journal Articles

The Relative Significance of ZAP -70 Promoter Methylation As a Prognostic Factor in Previously Untreated Chronic Lymphocytic Leukemia: Validation of Results Using a Second Large CLL Research Consortium (CRC) Patient Data Set

Rainer Claus, MD, Amy S. Ruppert, MAS, David M. Lucas, PhD, Manuela Zucknick, PhD, Laura Z. Rassenti, Ph.D., Andrew Greaves, Donna S. Neuberg, ScD, William G. Wierda, MD, Ph.D., Michael J. Keating, MD, Jennifer R. Brown, MD, PhD, John G Gribben, Kanti R. Rai, M.D., Michael R. Grever, MD, Neil E. Kay, MD, Thomas J. Kipps, MD, PhD, Christoph Plass, PhD, John C. Byrd, MD

Blood (2012) 120 (21): 3865.

https://doi.org/10.1182/blood.V120.21.3865.3865

Published: 2012

Journal Articles

Spontaneous Apoptosis of Chronic Lymphocytic Leukemia (CLL) Cells Correlates with Disease Burden and Inversely Correlates with Intracellular Levels of Signal Transducer and Activator of Transcription-3 (STAT3)

Rozovski Uri, MD, David Harris, Ping Li, PhD, Zhiming Liu, Srdana Grgurevic, Susan Lerner, MS, Matthew Martinez, William G. Wierda, MD, Ph.D., Michael Keating, MD, Zeev Estrov, MD, PhD

Blood (2012) 120 (21): 3910.

https://doi.org/10.1182/blood.V120.21.3910.3910

Published: 2012

Journal Articles

Incidence and Prognostic Impact of Cytogenetic and Molecular Clonal Evolution in Relapsed and Refractory Acute Myeloid Leukemia (AML) Patients: Study of Sequential Cytogenetic and Molecular Mutational Analysis.

Koichi Takahashi, MD, Hagop M. Kantarjian, MD, Lynne V. Abruzzo, MD, PhD, Gautam Borthakur, M.D., Guillermo Garcia-Manero, MD, Susan O'Brien, M.D., Stefan Faderl, MD, Rajyalakshmi Luthra, Ph.D., William G. Wierda, MD, Ph.D., Alessandra Ferrajoli, Sherry A. Pierce, RN, BS, Farhad Ravandi, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 2562.

https://doi.org/10.1182/blood.V120.21.2562.2562

Published: 2012

NARROW

Comparing Outcomes of Patients with Secondary AML: Treatment-Related MDS/AML, AML Secondary to Myeloproliferative Neoplasms (t-MPN), and AML with Prior Malignancies

Efficacy of PRT060318, a Novel Highly Specific SYK Inhibitor, in Acute Lymphoblastic Leukemia (ALL)

In Vitro Effects of PI3Kδ Inhibitor GS-1101 (Cal-101) in Acute Lymphoblastic Leukemia (ALL)

Signal Transducer and Activator of Transcription (STAT)-3-Dependent Regulation of Non-Coding RNA Genes in Chronic Lymphocytic Leukemia (CLL).

Is Chronic Lymphocytic Leukemia Still Incurable?

Very High Rate of Leukemic Transformation and Poor Survival in Patients with Lower Risk Myelodysplastic Syndrome (MDS) Who Dynamically Acquire FLT3 Molecular Alteration (FLT3m): Study of 290 MDS Patients with Sequential Mutation Analysis

Statins Use Improves the Clinical Outcomes of Salvage Therapy in Relapsed/Refractory CLL

Results of Second Generation Tyrosine Kinase Inhibitor Frontline Therapy in Chronic Myeloid Leukemia with Variant Philadelphia Chromosome

The Relative Significance of ZAP -70 Promoter Methylation As a Prognostic Factor in Previously Untreated Chronic Lymphocytic Leukemia: Validation of Results Using a Second Large CLL Research Consortium (CRC) Patient Data Set

Spontaneous Apoptosis of Chronic Lymphocytic Leukemia (CLL) Cells Correlates with Disease Burden and Inversely Correlates with Intracellular Levels of Signal Transducer and Activator of Transcription-3 (STAT3)

Incidence and Prognostic Impact of Cytogenetic and Molecular Clonal Evolution in Relapsed and Refractory Acute Myeloid Leukemia (AML) Patients: Study of Sequential Cytogenetic and Molecular Mutational Analysis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only